An observational study in Diabetes and Heart Failure, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-05-06.
Sponsored by Federico II University · Observational
The study has been carried out to determine diagnostic and therapeutic pathways in a group of HF diabetic patients and to verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy.
406 patients affected with heart failure and Type 2 Diabetes Mellitus, referred to Cardiologists and Diabetologists of pertaining healthcare districts in Campania, and followed for at least one year between 2018 and 2019, were enrolled in this retrospective study and divided in Group A, composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%) and Group B, formed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%). All patients had performed periodic clinical evaluations and an echocardiographic exam every 12 months. Anthropometric parameters, HF etiology, co-morbidities, complications and ongoing therapies were collected.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 406 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Federico II University is the lead sponsor of 356 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A total of 406 patient with HF and T2DM, referred to ARCA Cardiologists from 17 healthcare districts in Campania and to AMD Physicians from 8 Antidiabetic Centers and followed for at least one year between 2018 and 2019, were enrolled.
Exclusion Criteria:
It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (\>45%).
Drug: Antidiabetic
It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
Drug: Antidiabetic
Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Also known as: SGLT2 inhibitors, gliflozins, echocardiography.
Total Cholesterol, LDL, HDL Triglycerides, Creatinine
mg/dl
Time frame: 12 months
B-type natriuretic peptide (BNP)
pmol/m
Time frame: 12 months
HbA1c
mmol/L
Time frame: 12 months
Ejection Fraction
Time frame: 12 months
Left Ventricular End-Diastolic Volume Index (LV-EDVi), Left Ventricular End-Systolic Volume Index (LV-ESVi), Left Atrial Volume Index (LAVi)
ml/m2
Time frame: 12 months
E velocity, A velocity,E' velocity
m/sec
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federico II University